CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the collaboration and license agreement with CSL to develop Fc multimer programs, including M230, executed by the Company on January 5, 2017.
With the termination of the applicable waiting period under the HSR Act, the collaboration and license agreement with CSL is effective as of February 17, 2017. Under the license agreement, CSL will pay Momenta a $50 million upfront cash payment within 30 days of the effective date.
Additional details regarding the collaboration can be found in Momenta’s Form 8-K filed with the Securities and Exchange Commission on January 5, 2017.
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.MOMENTA INVESTOR CONTACT:
MOMENTA MEDIA CONTACT:
MacDougall Biomedical Communications